Duchenne muscular dystrophy (DMD) is caused by abnormalities in the dystrophin gene and is clinically characterised by childhood muscle degeneration and cardiomyopathy. We produced an induced pluripotent stem cell line from a DMD patient's dermal fibroblasts by electroporation with episomal vectors containing: hL-MYC, hLIN28, hSOX2, hKLF4, hOCT3/4. The resultant DMD iPSC line (CCMi001DMD-A-3) displayed iPSC morphology, expressed pluripotency markers, possessed trilineage differentiation potential and was karyotypically normal. MLPA analyses performed on DNA extracted from CCMi001DMD-A-3 showed a deletion of exons 49 and 50 (CCMi001DMD-A-3, Δ49, Δ50).
Resource utility
This tool is valuable for the identification of novel DMD pathophysiological mechanisms downstream of dystrophin mutations and for screening putative therapies.
Resource details
Duchenne muscular dystrophy (DMD) is a severe early onset form of muscular dystrophy (MD) caused by either spontaneous mutations or Stem Cell Research 25 (2017) (Okita et al. 2007 ) and cultured under feeder-free defined conditions. After 31 days of reprogramming, iPSC colonies were manually selected and culture expanded. The iPSC line described in this publication was named CCMi001DMD-A-3, and entered iPSC characterisation by evaluating: distinctive iPSC-like morphology and expression of the pluripotency markers by immunocytochemistry and FACS analyses (SSEA4, Sox2, Nanog and Oct4, Fig and endodermal lineages (Nestin, αSMA and Sox17, Fig. 1C ). Cytogenetic analysis was conducted on 30 mitosis from two independent cultures. The CCMi001DMD-A-3, iPSC line was karyotypically normal (size, shape, and number of chromosomes) at P23 (Fig. 1D) . To detect the specific dystrophin mutation present in the CCMi001DMD-A-3 iPSC line, multiple ligation probe amplification (MLPA) analyses was performed on DNA extracted from CCMi001DMD-A-3 and a control iPSC line (derived from a healthy control subject's dermal fibroblasts). CCMi001DMD-A-3, showed a deletion of exons 49 and 50 (CCMi001DMD-A-3, Δ49, Δ50; Fig. 1E ). Disruption of the DMD reading frame was confirmed by measuring the expression of dystrophin protein in functional CMs derived from CCMi001DMD-A-3, Δ49, Δ50 (DMD-A-3-CMs) by western blot and comparing it to CMs derived from iPSCs obtained from a healthy control subject's dermal fibroblasts (Control-CMs; Fig. 1E inset) . DMD-A-3-CMs did not display full-length dystrophin protein expression (Fig. 1E inset, lane 2) which was observed at 427 kDa in Control-CMs (Fig. 1E inset, lane 1) .
Materials and methods

Reprogramming of DMD patient's fibroblasts to iPSCs
All investigations were conducted according to the principles stated in the Declaration of Helsinki. Following informed consent under the regulations of the local ethics committee (European Institute of Oncology and Centro Cardiologico Monzino, Italy) the patient's fibroblasts were isolated from a skin biopsy by explant culture. Fibroblasts were transfected with episomal vectors (pCXLE-hUL, pCXLE-hSK, pCXLEhOCT3/4; Addgene) by electroporation (Neon™ transfection system, Invitrogen), transferred into a single well of a 6 well plate pre-coated with human recombinant vitronectin (Life Technologies) and cultured at 37°C with 5% CO 2 . On day 3 post transfection transfected fibroblast media was replaced with reprogramming media (ReproTeSR™, Stemcell Technologies) which was changed every day. Colonies were harvested when they reached 1000 μm in diameter by manual isolation using a 25 gauge sterile syringe and transferred into an individual well of a 12-well plate containing mTeSR1™ media (Stemcell Technologies) supplemented with RevitaCell™ (Life Technologies). iPSCs were maintained in mTeSR1™ media with daily media changes. At 80-90% confluency, iPSCs were non-enzymatically passaged (every 3-4 days) with ReLeSR™ (Stemcell Technologies) and replated as small aggregates in mTeSR1™ media containing RevitaCell™. Stock vials of iPSCs were harvested in mFreSR™ (Stemcell Technologies) and stored at −180°C for future experiments (Table 1) .
Pluripotency marker immunocytochemistry
CCMi001DMD-A-3, Δ 49, Δ 50 iPSCs were cultured until confluent, split and transferred to vitronectin-coated chamber slides for analysis of pluripotency proteins. iPSCs were analysed with a confocal microscope (LSM710, Zeiss). All antibody details are listed in Table 2 .
Flow cytometry
CCMi001DMD-A-3, Δ 49, Δ 50 were dissociated using Gentle Cell Dissociation Reagent (Stemcell Technologies). Non-specific staining was blocked using 5% Bovine Serum Albumin (BSA; Sigma-Aldrich) in PBS (Lonza). Cells were stained with a SSEA4 (1:100, 1 h; ab16287 Abcam) per reaction followed by goat anti-mouse IgM-FITC (1:200, 1 h; A11659 Life Technologies). Cells were analysed using a FACSCalibur™ flow cytometer (BD Biosciences).
In vitro trilineage differentiation potential assay
CCMi001DMD-A-3, Δ 49, Δ 50 iPSCs were subjected to monolayer differentiation using the STEMdiff™ trilineage differentiation kit (Stemcell Technologies) according to the manufacturer's instructions. On day 5 mesodermal-and endodermal-induced cells were fixed (4% formaldehyde, 3 min at RT) and permeabilised (0.5% triton, 3 min at RT). Unspecific binding was blocked in 3% BSA (2 h RT) and expression of αSMA and Sox17 were evaluated. Following 7 days of ectodermalinduction, cells were fixed, permeabilized and blocked as before and expression of Nestin was evaluated. Differentiated cells were analysed by confocal microscopy (LSM710, Zeiss). All antibody details are listed in Table 2 .
Karyotyping
Metaphase chromosomes were prepared from CCMi001DMD-A-3, Δ 49, Δ 50 cultures at passage 23 (P23). After 48-96 h colcemid (10 μg/ml) was added for 3 h at 37°C. iPSCs were incubated in hypotonic solution (Sodium Citrate 0.6%, KCl 0.13%) at RT for 10 min, washed with Ibraimov solution (acetic acid 5%), fixed in Optichrome (28°C, 42% rH) with methanol/acetic acid (3:1), Q-banded and photographed. Karyotype images were obtained at 100× magnification (Olympus BX microscope, U-CMAD3 Olympus camera). Metaphases (30) at approximately the 400 band level were analysed and karyotyped using an automated cytogenetic imaging system (MetaSystems Gmbh, Germany).
Dystrophin mutation analyses by multiple ligation probe amplification (MLPA)
Genomic DNA was extracted from iPSCs using the QIAamp DNA Mini Kit (Qiagen) according to manufacturer's instructions. The MLPA reaction was performed to detect all 79 exons of dystrophin gene using the SALSA MLPA probe sets P034 and P035 (MRC Holland), following the manufacturer's instructions. The amplified products were run on the ABI PRISM 3130 genetic analyser (Applied Biosystems) and the obtained data were analysed using Coffalyser software (MRC Holland). DNA extracted from iPSCs obtained from a healthy individual's dermal fibroblast-derived iPSCs were used as controls and included in the run.
Dystrophin expression in iPSC cardiomyocytes
Differentiation of CCMi001DMD-A-3, Δ 49, Δ50 along the cardiomyogenic lineage was performed following a monolayer small molecule-based directed differentiation protocol (Lian et al. 2013) . Following 7 days of sustained beating (differentiation day 16), cardiomyocytes were processed for the determination of dystrophin and gapdh protein expression by western immunoblot analysis. All antibody details are listed in Table 2 .
